Population 2017 |
105 million |
| |
| | | | | |
Estimates of TB burden*, 2017 |
Number (thousands) |
Rate (per 100 000 population) |
Mortality (excludes HIV+TB) |
26 |
(23–31) |
25 |
(22–29) |
Mortality (HIV+TB only) |
0.38 |
(0–3.3) |
0.36 |
(0–3.1) |
Incidence (includes HIV+TB) |
581 |
(326–909) |
554 |
(311–866) |
Incidence (HIV+TB only) |
7 |
(2.9–13) |
6.6 |
(2.8–12) |
Incidence (MDR/RR-TB)** |
27 |
(12–47) |
26 |
(12–45) |
| |
| | | | | |
Estimated TB incidence by age and sex (thousands)*, 2017 |
|
0-14 years |
> 14 years |
Total |
Females |
34 |
(9.2–59) |
139 |
(38–241) |
173 |
(59–287) |
Males |
37 |
(10–65) |
371 |
(100–641) |
408 |
(140–676) |
Total |
71 |
(31–112) |
510 |
(222–798) |
581 |
(326–909) |
| |
| | | | | |
TB case notifications, 2017 |
|
Total cases notified |
328 773 |
Total new and relapse |
317 266 |
- % tested with rapid diagnostics at time of diagnosis |
26% |
- % with known HIV status |
24% |
- % pulmonary |
98% |
- % bacteriologically confirmed among pulmonary |
39% |
| |
| | | | | |
Universal health coverage and social protection |
|
TB treatment coverage (notified/estimated incidence), 2017 |
55% (35–97) |
TB patients facing catastrophic total costs, 2017 |
35% |
TB case fatality ratio (estimated mortality/estimated incidence), 2017 |
0.05 (0.03–0.08) |
| |
| | | | | |
TB/HIV care in new and relapse TB patients, 2017 |
Number |
(%) |
Patients with known HIV-status who are HIV-positive |
1 335 |
2% |
- on antiretroviral therapy |
1 185 |
89% |
| |
| | | | | |
Drug-resistant TB care, 2017 |
New cases |
Previously treated cases |
Total number*** |
Estimated MDR/RR-TB cases among notified pulmonary TB cases |
|
20 000 (18 000–22 000) |
Estimated % of TB cases with MDR/RR-TB |
2.6% (1.9–3.4) |
28% (27–28) |
|
% notified tested for rifampicin resistance |
19% |
83% |
93 058 |
MDR/RR-TB cases tested for resistance to second-line drugs |
|
2 401 |
Laboratory-confirmed cases |
MDR/RR-TB: 6 438, XDR-TB: 15 |
Patients started on treatment **** |
MDR/RR-TB: 5 623, XDR-TB: 16 |
| |
| | | | | |
Treatment success rate and cohort size |
Success |
Cohort |
New and relapse cases registered in 2016 |
91% |
332 308 |
Previously treated cases, excluding relapse, registered in 2016 |
80% |
10 097 |
HIV-positive TB cases registered in 2016 |
82% |
989 |
MDR/RR-TB cases started on second-line treatment in 2015 |
54% |
3 851 |
XDR-TB cases started on second-line treatment in 2015 |
33% |
9 |
| |
| | | | | |
TB preventive treatment, 2017 |
|
% of HIV-positive people (newly enrolled in care) on preventive treatment |
57% |
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment |
12% (11–13) |
| |
| | | | | |
TB financing, 2018 |
|
National TB budget (US$ millions) |
160 |
Funding source: 37% domestic, 21% international, 42% unfunded |
| |
| | | | | |
* Ranges represent uncertainty intervals | | | | | |
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
*** Includes cases with unknown previous TB treatment history | | | | |
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed | | |
| | | | | |